Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| LGND | LIGAND PHARMACEUTICALS INC | 2026-04-02 15:10:04 | 199.59 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LGND | 0000886163 | LIGAND PHARMACEUTICALS INC | US53220K5048 | 5493008K7TB0IKP37H79 | 770160744 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 3911 SORRENTO VALLEY BLVD | SAN DIEGO | CA | 92121 | UNITED STATES | US | 858-550-7500 | 3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA, 92121 | 3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA, 92121 | LIGAND PHARMACEUTICALS | — | 1987 | Todd C. Davis | 68 | http://ligand.com | 1,600,000,000 | 19,774,000 | 19,941,141 | Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. | 2026-04-02 16:32:45 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 1,600,000,000 | 500,000,000 | 45.4545 | 19,941,141 | 685,788 | 3.5615 |
| 2024 | 1,100,000,000 | 200,000,000 | 22.2222 | 19,255,353 | 1,550,066 | 8.7548 |
| 2023 | 900,000,000 | -100,000,000 | -10 | 17,705,287 | 628,629 | 3.6812 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Andrew Reardon | Chief Legal Officer, Secretary | 2024 | 451,950 | — | 1,428,806 | 240,000 | 7,380 | 3,270,956 |
| Matthew Korenberg | Chief Operating Officer, President | 2024 | 385,545 | — | 6,716,643 | 142,789 | 118,326 | 13,165,669 |
| Todd C. Davis | Chief Executive Officer | 2024 | 695,834 | — | 6,429,536 | 637,000 | 9,960 | 12,914,980 |
| Tavo Espinoza | Chief Financial Officer | 2024 | 469,550 | — | 1,428,806 | 250,000 | 7,380 | 3,298,556 |
| Andrew Reardon | Chief Legal Officer, Secretary | 2023 | 434,262 | — | 1,126,169 | 173,705 | 6,900 | 2,337,081 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 47 |
| 2024 | 68 |
| 2023 | 58 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 268,087,000 | 167,133,000 | 131,314,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 81,182,000 | 21,425,000 | 24,537,000 |
| General And Administrative Expenses | 92,449,000 | 78,654,000 | 52,790,000 |
| Operating Expenses | — | — | — |
| Operating Income | 41,002,000 | -22,606,000 | 11,942,000 |
| Net Income | 124,453,000 | -4,032,000 | 52,154,000 |
| Earnings Per Share Basic | 6.44 | -0.22 | 3.02 |
| Earnings Per Share Diluted | 6.13 | -0.22 | 2.94 |
| Weighted Average Shares Outstanding Basic | 19,338,000 | 18,290,000 | 17,298,000 |
| Weighted Average Shares Outstanding Diluted | 20,294,000 | 18,290,000 | 17,757,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 174,927,000 | 72,307,000 | 22,954,000 |
| Marketable Securities Current | 558,594,000 | 183,858,000 | 147,355,000 |
| Accounts Receivable | 59,601,000 | 38,376,000 | 32,917,000 |
| Inventories | 9,126,000 | 14,114,000 | 23,969,000 |
| Non Trade Receivables | 1,446,000 | 4,073,000 | 6,395,000 |
| Other Assets Current | 5,785,000 | 16,897,000 | 2,657,000 |
| Total Assets Current | 832,271,000 | 331,559,000 | 237,429,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 3,571,000 | 15,133,000 | 15,607,000 |
| Other Assets Non Current | 12,582,000 | 6,924,000 | 5,923,000 |
| Total Assets Non Current | 728,366,000 | 610,215,000 | 549,787,000 |
| Total Assets | 1,560,637,000 | 941,774,000 | 787,216,000 |
| Accounts Payable | 3,238,000 | 5,233,000 | 2,427,000 |
| Deferred Revenue | 621,000 | 1,278,000 | 1,222,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 135,000 | 27,906,000 | 12,467,000 |
| Total Liabilities Current | 37,447,000 | 37,112,000 | 16,782,000 |
| Long Term Debt | 446,192,000 | — | — |
| Other Liabilities Non Current | 16,629,000 | 30,163,000 | 27,758,000 |
| Total Liabilities Non Current | 505,978,000 | 74,223,000 | 69,521,000 |
| Total Liabilities | 543,425,000 | 111,335,000 | 86,303,000 |
| Common Stock | 20,000 | 20,000 | 18,000 |
| Retained Earnings | 608,088,000 | 498,984,000 | 503,016,000 |
| Accumulated Other Comprehensive Income | 8,455,000 | -5,942,000 | -817,000 |
| Total Shareholders Equity | 1,017,212,000 | 830,439,000 | 700,913,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 33,775,000 | 35,239,000 | 36,521,000 |
| Share Based Compensation Expense | 46,849,000 | 41,089,000 | 25,743,000 |
| Other Non Cash Income Expense | 1,022,000 | -20,010,000 | 250,000 |
| Change In Accounts Receivable | 21,737,000 | 6,459,000 | 2,601,000 |
| Change In Inventories | -4,988,000 | -9,619,000 | 10,870,000 |
| Change In Non Trade Receivables | -2,667,000 | -2,310,000 | 1,781,000 |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 5,882,000 | 13,903,000 | -4,704,000 |
| Change In Other Liabilities | 3,887,000 | -1,291,000 | 9,865,000 |
| Cash From Operating Activities | 49,359,000 | 97,047,000 | 49,577,000 |
| Purchases Of Marketable Securities | 726,713,000 | 226,384,000 | 126,764,000 |
| Sales Of Marketable Securities | 159,584,000 | 229,367,000 | 148,765,000 |
| Acquisition Of Property Plant And Equipment | 452,000 | 1,821,000 | 3,521,000 |
| Acquisition Of Business | 0 | 0 | 10,405,000 |
| Other Investing Activities | — | 0 | 0 |
| Cash From Investing Activities | -377,322,000 | -143,664,000 | -11,682,000 |
| Tax Withholding For Share Based Compensation | 9,599,000 | 5,136,000 | 4,547,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 0 | 37,140,000 | — |
| Repurchase Of Common Stock | 15,000,000 | 0 | 0 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 0 | 0 | 76,854,000 |
| Other Financing Activities | 47,100,000 | 65,200,000 | 22,200,000 |
| Cash From Financing Activities | 428,223,000 | 97,141,000 | -59,947,000 |
| Change In Cash | 102,620,000 | 49,353,000 | -22,052,000 |
| Cash At End Of Period | 174,927,000 | 72,307,000 | 22,954,000 |
| Income Taxes Paid | 7,802,000 | 19,206,000 | 8,770,000 |
| Interest Paid | 321,000 | 263,000 | 288,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 6.44 | -0.22 | 3.02 |
| Price To Earnings Ratio | 29.3587 | -487.0455 | 23.649 |
| Earnings Growth Rate | -3,027.2727 | -107.2848 | -252.5253 |
| Price Earnings To Growth Ratio | -0.0097 | 4.5397 | -0.0937 |
| Book Value Per Share | 52.6017 | 45.404 | 40.5199 |
| Price To Book Ratio | 3.5944 | 2.3599 | 1.7626 |
| Ebitda | 170,745,000 | 53,450,000 | 98,101,000 |
| Enterprise Value | 3,927,500,660 | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.4386 | — | — |
| Capital Expenditures | 22,213,000 | 34,765,000 | 39,646,000 |
| Free Cash Flow | 27,146,000 | 62,282,000 | 9,931,000 |
| Return On Equity | 0.1223 | -0.0049 | 0.0744 |
| One Year Beta | 0.8502 | 1.3466 | 0.8633 |
| Three Year Beta | 0.9588 | 1.1787 | 1.133 |
| Five Year Beta | 1.0818 | 1.1213 | 1.1343 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| KOZARICH JOHN W | Director | 2026-04-01 | 79 | D | 42,455 |
| KOZARICH JOHN W | Director | 2026-04-01 | 43 | D | 42,412 |
| KOZARICH JOHN W | Director | 2026-04-01 | 159 | D | 42,253 |
| Reardon Andrew | CLO & Secretary | 2026-04-01 | 5,000 | A | 46,382 |
| Reardon Andrew | CLO & Secretary | 2026-04-01 | 460 | D | 45,922 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | 2026-02-13 | CA31 | Purchase | 2026-01-15 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2026-02-13 | CA31 | Purchase | 2026-01-05 | — | $1,001 - $15,000 |
| Lamar Smith | 2018-01-09 | TX21 | Purchase | 2017-12-01 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 81,111,786 | 429,004 | 189.07 |
| GROUP ONE TRADING LLC | 2025-12-31 | 558,324 | 2,953 | 189.0701 |
| PICTON MAHONEY ASSET MANAGEMENT | 2025-12-31 | 2,080 | 11 | 189.0909 |
| Ameritas Investment Partners, Inc. | 2025-12-31 | 301,378 | 1,594 | 189.0703 |
| ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ | 2025-12-31 | 567 | 3 | 189 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Direxion Shares ETF Trust | 2026-01-31 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | PILL | 1,392 | 267,403.2 | 1.4911 |
| Global X Funds | 2026-01-31 | Global X Russell 2000 ETF | RSSL | 8,814 | 1,693,169.4 | 0.1222 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 15,292 | 2,937,593.2 | 0.1098 |
| AIM INVESTMENT FUNDS (INVESCO INVESTMENT FUNDS) | 2026-01-31 | Class R | GTHRX | 40,048 | 7,693,220.8 | 0.6251 |
| AIM INVESTMENT FUNDS (INVESCO INVESTMENT FUNDS) | 2026-01-31 | Class Y | GGHYX | 40,048 | 7,693,220.8 | 0.6251 |